This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Pim-1 (PIM1); PIM2; PIM3	<i>In vitro</i> and mouse studies identified PIM1-, PIM2- and PIM3-inhibiting benzothienopyrimidinone compounds that could help treat cancer. The compounds had antiproliferative activity against two human leukemia cell lines and had nanomolar K_i values against all three PIM kinases. In mice, one of the compounds had good pharmacokinetics and bioavailability. Next steps could include testing the compounds in animal models of cancer. SuperGen Inc.'s SGI-1776, a selective PIM1 inhibitor, is in Phase I testing to treat cancers.	Patent and licensing status unavailable	Tao, Z. <i>et al. J. Med. Chem.</i> ; published online Oct. 16, 2009; doi:10.1021/jm900943h Contact: Zhi-Fu Tao, Abbott Laboratories, Abbott Park, Ill. e-mail: zhi-fu.tao@abbott.com
<i>SciBX</i> 2(43); doi:10.1038/scibx.2009.1596 Published online Nov. 5, 2009				